Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipalolitovolimab + tuvonralimab + lenvatinib
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of ipalolitovolimab (JS004), tuvonralimab (toripalimab; JS001), and lenvatinib. Ipalolitovolimab is a first-in-class recombinant humanized monoclonal antibody targeting B- and T-lymphocyte attenuator (BTLA), a co-inhibitory molecule expressed on T and B lymphocytes that negatively regulates immune responses. Tuvonralimab is a humanized monoclonal antibody directed against the programmed cell death protein 1 (PD-1) receptor, designed to block the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby restoring T-cell mediated anti-tumor activity. Lenvatinib is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET. The combination is being investigated, particularly by institutions like Zhejiang Tumor Hospital, for the treatment of advanced malignancies such as pleural mesothelioma, aiming to leverage the synergistic effects of dual checkpoint inhibition (BTLA and PD-1) alongside anti-angiogenic and multi-kinase inhibition.
- Brand names
- Tuoyi
- Other names
- JS004 + JS001 + LenvatinibIpalolitovolimab + Toripalimab + Lenvatinib
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)BTLA
Beyond the preview
Go deeper on ipalolitovolimab + tuvonralimab + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipalolitovolimab + tuvonralimab + lenvatinib.